[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100053899":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":31,"responsibleParty":88,"collaborators":11,"id":90,"slug":91,"hasResults":92,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":92,"sex":98,"minAge":99,"maxAge":100,"enrollmentInfo":101,"targetDuration":11,"studyType":104,"phases":105,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":34,"whyStopped":11,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},{"fullName":5,"class":6},"Centre Jean Perrin","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"cDNA detection","EXPERIMENTAL",null,[13],"Biological: blood sampling",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"BIOLOGICAL","blood sampling","The intervention consist in blood samples (18mL) collected 1 and 3-months after the end of chemoradiotherapy",[9],[21],{"name":22,"affiliation":5,"role":23},"Maureen BERNADACH Coordinator, MD","STUDY_DIRECTOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":29,"email":30},"Angeline GINZAC COUVÉ Project manager, PhD","CONTACT","0463663337","+33","angeline.ginzac@clermont.unicancer.fr",[32,51,66,77],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"CH Henri Mondor Aurillac","RECRUITING","Aurillac","CANTAL","15000","France","FR",{"type":41,"coordinates":42},"Point",[43,44],2.43983,44.92539,{"lat":44,"lon":43},[47],{"name":48,"role":27,"phone":49,"phoneExt":11,"email":50},"Daniela BURLACU, Dr","0471465613","d.burlacu@ch-aurillac.fr",{"facility":52,"status":34,"city":53,"state":54,"zip":55,"country":38,"countryCode":39,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"Centre Jean PERRIN","Clermont-Ferrand","Puy-de-Dôme","63011",{"type":41,"coordinates":57},[58,59],3.08682,45.77969,{"lat":59,"lon":58},[62,64],{"name":63,"role":27,"phone":28,"phoneExt":29,"email":30},"Angeline GINZAC Project manager, PhD",{"name":22,"role":65,"phone":11,"phoneExt":11,"email":11},"PRINCIPAL_INVESTIGATOR",{"facility":67,"status":34,"city":68,"state":11,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"Hôpital de la Croix-Rousse","Lyon",{"type":41,"coordinates":70},[71,72],4.84789,45.74906,{"lat":72,"lon":71},[75],{"name":76,"role":65,"phone":11,"phoneExt":11,"email":11},"Philippe CÉRUSE, Pr",{"facility":78,"status":34,"city":79,"state":11,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"CHU de Saint-Étienne","Saint-Etienne",{"type":41,"coordinates":81},[82,83],4.39,45.43389,{"lat":83,"lon":82},[86],{"name":87,"role":65,"phone":11,"phoneExt":11,"email":11},"Yann LELONGE, Dr",{"type":89,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100053899","cdna-and-residual-disease-after-chemoradiotherapy-for-locally-advanced-head-and-neck-squamous-cell-carcinomas-100053899",false,"NCT07178847","cDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinomas","Evaluation of Circulating DNA as a Biomarker of Residual Disease After Chemoradiotherapy for Locally Advanced Head and Necksquamous Cell Carcinoma","NeckTAR-IN","Selection Criteria:\n\n* Patient included in NeckTAR study\n* Written informed consent signed for NeckTAR-IN study\n* Affiliation to the French social security system","ALL","18 Years","80 Years",{"count":102,"type":103},59,"ESTIMATED","INTERVENTIONAL",[106],"NA","The goal of this ancillary clinical trial is to evaluated circulating DNA as a biomarker of residual disease after chemoradiotherapy for locally advanced head and neck squamous cell carninoma.\n\nThe main question it aims to answer is :\n\n\\- Does circulating DNA (cDNA) be able to detect residual disease 3 months after the end of chemoradiotherapy ? Researchers will compare detection of cDNA at 3-months and objective response (clinical and radiological).\n\nParticipants will :\n\n* be included in the main study (Neck-TAR)\n* have a blood sample 1 and 3-month after the end of treatment",[109],"Locally Advanced Head and Neck Carcinoma",[111,112],"circulating DNA","residual disease","2026-07-10",{"date":115,"type":116},"2026-07-13","ACTUAL",{"date":118,"type":116},"2025-10-13",{"date":120,"type":103},"2031-07",{"name":5,"class":6},4]